Elective oophorectomy in the gynecological patient: When is it desirable?

Current Opinion in Obstetrics and Gynecology

Volumn 19, Issue 4, 2007, Pages 350-354

  Parker, William H ^a,f   Shoupe, Donna ^b   Broder, Michael S ^a   Liu, Zhimei ^c   Farquhar, Cindy ^d   Berek, Jonathan S ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c Cerner Health Insights   (United States)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NONE   (United States)

Author keywords

Elective oophorectomy; Hysterectomy; Oophorectomy; Prophylactic oophorectomy

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BRCA1 PROTEIN; BRCA2 PROTEIN; ESTRADIOL; ESTROGEN; GESTAGEN; RALOXIFENE;

BREAST CANCER; CANCER PREVENTION; CARDIOVASCULAR DISEASE; DEMENTIA; DISEASE SEVERITY; ELECTIVE SURGERY; ENDOMETRIOSIS; GERM LINE; HIGH RISK POPULATION; HIP FRACTURE; HUMAN; HYSTERECTOMY; INCIDENCE; MENOPAUSAL SYNDROME; MORTALITY; MUTATION; OVARIECTOMY; OVARY CANCER; PARKINSON DISEASE; PATIENT SELECTION; PREGNANCY; PRIORITY JOURNAL; PROPHYLAXIS; PROTECTION; REVIEW; RISK BENEFIT ANALYSIS; SEXUAL FUNCTION; SURGICAL TECHNIQUE; UROGENITAL TRACT MALFORMATION;

CARDIOVASCULAR DISEASES; FEMALE; HUMANS; HYSTERECTOMY; OVARIAN NEOPLASMS; OVARIECTOMY; RISK FACTORS; SURGICAL PROCEDURES, ELECTIVE;

EID: 34447561726     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/GCO.0b013e32821642d1     Document Type: Review

References (35)

1. Gibbs E. Suggested prophylaxis for ovarian cancer. Am J Obstet Gynecol 1971; 111:756-765.
2. Sluijmer A, Heineman M, De Jong F, Evers J. Endocrine activity of the postmenopausal ovary: the effect of pituitary down-regulation and oophorectomy. J Clin Endocrinol Metab 1995; 80:2163-2167.
3. Judd HL, Judd GE, Lucas WE, Yen SSC. Endocrine function of the postmenopausal ovary: concentrations of androgens and estrogens in ovarian and peripheral vein blood. J Clin Endocrinol Metab 1974; 39:1020-1024.
4. Laughlin GA, Barrett-Connor E, Kritz-Silverstein D, Von Muhlen D. Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: the Rancho Bernardo Study. J Clin Endocrinol Metab 2000; 85:645-651.
5. Wuest J, Dry T, Edwards J. The degree of coronary atherosclerosis in bilaterally oophorectomized women. Circulation 1953; 7:801-809.
6. Hodis H, Mack W. Atherosclerosis imaging methods: assessing cardiovascular disease and evaluating the role of estrogen in the prevention of atherosclerosis. Am J Cardiol 2002; 89:19E-27E.
7. Mack W, Slater C, Xiang M, et al. Elevated subclinical atherosclerosis associated with oophorectomy is related to time since menopause rather than type of menopause. Fertil Steril 2004; 82:391-397.
8. Colditz G, Willett W, Stampfer M, et al. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987; 316:1105-1110.
9. Cummings S, Browner W, Bauer D, et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. N Engl J Med 1998; 339:733-738.
10. Melton J, Khosla S, Malkasian G, et al. Fracture risk after bilateral oophorectomy in elderly women. J Bone Miner Res 2003; 18:900-905.
11. Keene G, Parker M, Pryor G. Mortality and morbidity after hip fractures. BMJ 1993; 13:1248-1250.
12. Rocca W, Grossardt BR, de Andrade M, et al. Survival patterns after oophorectomy in premenopausal women: a population based cohort study. Lancet Oncol 2006; 10:821-828. A population-based study that showed that the risk of death increased for women having oophorectomy before the age of 45 years.
13. MacLennan AH, Henderson VW, Paine B, et al. Hormone therapy, timing of initiation, and cognition in women aged older than 60 years: the REMEMBER pilot study. Menopause 2006; 13:6-7.
14. Birge SJ. The role of estrogen deficiency in the aging central nervous system. In: Lobo RA, editor. Treatment of the postmenopausal woman; basic and clinical aspects. Raven Press Ltd.: New York; 1996.
15. Nathorst-Boos J, von Schoultz B, Carlstrom K. Elective ovarian removal and estrogen replacement therapy - effects on sexual life, psychological well being and androgen status. J Psychosom Obstet Gynaecol 1993; 14:283-293.
16. Madalinska JB, van Beurden M, Bleiker EM, et al. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J Clin Oncol 2006; 24:3576-3582.
17. Parker W, Broder M, Liu Z, et al. Ovarian conservation at the time of hysterectomy for benign disease. Obstet Gynecol 2005; 106:219-226.
18. SEER 12 incidence and mortality, 1993-2001, follow-back year 1992. Surveillance, Epidemiology, and End Results (SEER) Program. DevCan database. Bethesda, MD, USA: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch; 2004.
19. CDC/National Center for Health Statistics, National Vital Statistics System. Table HIST002R_2. Death rates from 113 selected causes, by 5-year age groups, race and sex: United States, 1979-1998. Ischemic heart disease (410-414, 429.2), all races, female, 1998. p. 336. Available at: http://www.cdc.gov/nchs/ data/statab/hist002r_2.pdf. Accessed: April 2005
20. Arias E, Anderson R, Kung H, et al. Deaths: final data for 2001. Natl Vital Stat Rep 2003; 52:1-115.
21. Hankinson SE, Hunter DJ, Colditz GA, et al. Tubal ligation, hysterectomy, and risk of ovarian cancer: a prospective study. JAMA 1993; 270:2813-2818.
22. Cramer D, Titus-Ernstoff L, McLoanis J, et al. Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005; 14:1125-1131.
23. Parazzini F, Negri E, La Vecchia C, et al. Hysterectomy, oophorectomy, and subsequent ovarian cancer. Obstet Gynecol 1993; 81:363-366.
24. Schairer C, Persson I, Falkeborn M, et al. Breast cancer risk associated with gynecologic surgery and indications for such surgery. Int J Cancer 1997; 70:150-154.
25. Bailey CL, Ueland FR, Land GL, et al. The malignant potential of small cystic ovarian tumors in women over 50 years of age. Gynecol Oncol 1998; 69:3-7.
26. Parker WH, Levine RL, Howard FM, et al. A multicenter study of laparoscopic management of selected cystic adnexal masses in postmenopausal women. J Am Coll Surg 1994; 179:733-737.
27. Nardo LG, Kroon ND, Reginald PW. Persistent unilocular ovarian cysts in a general population of postmenopausal women: is there a place for expectant management? Obstet Gynecol 2003; 102:589-593.
28. Dekel A, Ewfrat Z, Orvieto R, et al. The residual ovary syndrome: a 20-year experience. Eur J Obstet Gynecol Reprod Biol 1996; 68:159-164.
29. Brett KM, Reuben CA. Prevalence of estrogen or estrogen-progestin hormone therapy use. Obstet Gynecol 2003; 102:1240-1249.
30. Buist DS, Newton KM, Miglioretti DL, et al. Hormone therapy prescribing patterns in the United States. Obstet Gynecol 2004; 104:1042-1050.
31. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004; 48:271-287.
32. Huser MA, Evans TS, Berger V. Medication adherence trends with statins. Adv Ther 2005; 22:163-171.
33. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72:1117-1130.
34. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346:1616-1622.
35. Armstrong K, Schwartz JS, Randall T, et al. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. J Clin Oncol 2004; 22:1045-1054.